Advertisement

Drugs & Aging

, Volume 33, Issue 9, pp 655–663 | Cite as

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

  • Alexandr Poprach
  • Radek Lakomy
  • Zbynek Bortlicek
  • Bohuslav Melichar
  • Tomas Pavlik
  • Ondrej Slaby
  • Rostislav Vyzula
  • Marek Svoboda
  • Igor Kiss
  • Hana Studentova
  • Milada Zemanova
  • Ondrej Fiala
  • Katerina Kubackova
  • Ladislav Dusek
  • Jana Hornova
  • Tomas Buchler
  • On behalf of the Czech Renal Cell Cancer Cooperative Group
Original Research Article

Abstract

Background

Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients.

Patients and Methods

The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged <70 and ≥70 years, respectively.

Results

Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8–11.8) and 8.8 months (7.2–10.4) for patients aged <70 and ≥70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9–35.9) and 26.3 months (21.3–31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events.

Conclusions

The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.

Keywords

Overall Survival Renal Cell Carcinoma Sunitinib Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We would like to thank the following heads of the comprehensive cancer centres for the permission to use data of patients from their respective regional networks: Dr Martina Chodacka, Chomutov Hospital and Masaryk Hospital, Usti nad Labem; Dr Vaclav Janovsky, Ceske Budejovice Hospital, Ceske Budejovice; Dr Otakar Bednarik, University Hospital, Brno; Dr Jana Prausova, Motol University Hospital, Prague; Dr David Feltl, University Hospital, Ostrava; Professor Jindrich Finek, University Hospital, Pilsen; Professor Jiri Petera, University Hospital, Hradec Kralove; Dr Lubomir Slavicek, Jihlava Hospital, Jihlava; Dr Jana Katolicka, St. Anna University Hospital, Brno; Professor Rostislav Vyzula, Masaryk Memorial Institute of Oncology, Brno; Dr Jiri Bartos, County Hospital, Liberec; Dr Martin Safanda, Na Homolce Hospital, Prague; Dr Renata Soumarova, Novy Jicin Hospital, Novy Jicin; Professor Jitka Abrahamova, Thomayer Hospital, Prague; Professor Lubos Petruzelka, General University Hospital, Prague; Dr Milan Kohoutek, T Bata Memorial Hospital, Zlin. We are also indebted to all physicians who provided data for the RENIS registry.

Compliance with Ethical Standards

Funding

Supported by Grant NV15-34678A, Ministry of Health Research Programme 2015–2022. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, Glaxo Smith Kline, Roche, and Novartis).

Conflict of interest

Tomas Buchler received honoraria for advisory boards and lectures from Novartis, Pfizer, and Roche. Bohuslav Melichar received honoraria for advisory boards and/or lectures from Novartis, Pfizer, Glaxo Smith Kline, Roche and Bayer. Alexandr Poprach received honoraria for lectures from Novartis, Roche and Bayer. Katerina Kubackova received honoraria for lectures from Novartis and travel grants from Pfizer and Bayer. Milada Zemanova received honoraria for advisory boards and/or lectures from Novartis and Glaxo Smith Kline and travel grants from Bayer and Novartis. Hana Studentova received honoraria for lectures from Novartis and Glaxo Smith Kline. All other authors declare no conflict of interest.

Supplementary material

40266_2016_390_MOESM1_ESM.docx (15 kb)
Online Supplementary Table 1 Dose changes during the treatment with sunitinib (DOCX 14 kb)
40266_2016_390_MOESM2_ESM.docx (14 kb)
Online Supplementary Table 2 Dosage at treatment initiation and the reason for sunitinib treatment discontinuation (DOCX 14 kb)

References

  1. 1.
    Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205.CrossRefPubMedGoogle Scholar
  2. 2.
    Zanardi E, Grassi P, Cavo A, et al. Treatment of elderly patients with metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2016;16:323–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11 (online). International Agency for Research on Cancer, Lyon, France, 2012.http://globocan.iarc.fr. Accessed on 28 Jan 2016.
  4. 4.
    Dusek L, Muzik J, Kubasek M,et al. Epidemiology of malignant tumours in the Czech Republic (online). Masaryk University, Brno, Czech Republic, 2005. http://www.svod.cz. Accessed on 28 Jan 2016.
  5. 5.
    Kristjansson SR, Wyller TB. Introduction. In: Schrijvers D, Aapro M, Zakotnik B, Audisio R, Halteren H, Hurria H, editors. ESMO handbook of cancer in senior patients. New York: Informa healthcare; 2010. p. 1–7.CrossRefGoogle Scholar
  6. 6.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  7. 7.
    National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. May 29, 2009. NIH publication # 09-7473.Google Scholar
  8. 8.
    Poprach A, Bortlíček Z, Büchler T, et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol. 2012;29:3314–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J ClinOncol. 2002;20:289–96.CrossRefGoogle Scholar
  10. 10.
    Bellmunt J, Négrier S, Escudier B, et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev OncolHematol. 2009;69:64–72.CrossRefGoogle Scholar
  11. 11.
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J ClinOncol. 2009;27:3584–90.CrossRefGoogle Scholar
  12. 12.
    Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Hutson TE, Bukowski RM, Rini BI, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110:1125–32.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Coward JIG,Larbi ED, Pandha HS, et al. The effect of age on first-line sunitinib treatment in patients with renal cell carcinoma (RCC). J Clin Oncol 2011;29 (suppl): abstract e15096.Google Scholar
  15. 15.
    Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol. 2013;24:336–42.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Alexandr Poprach
    • 1
  • Radek Lakomy
    • 1
  • Zbynek Bortlicek
    • 2
  • Bohuslav Melichar
    • 3
  • Tomas Pavlik
    • 2
  • Ondrej Slaby
    • 1
  • Rostislav Vyzula
    • 1
  • Marek Svoboda
    • 1
  • Igor Kiss
    • 1
  • Hana Studentova
    • 3
  • Milada Zemanova
    • 4
  • Ondrej Fiala
    • 5
    • 6
  • Katerina Kubackova
    • 7
  • Ladislav Dusek
    • 2
  • Jana Hornova
    • 8
  • Tomas Buchler
    • 8
  • On behalf of the Czech Renal Cell Cancer Cooperative Group
  1. 1.Department of Comprehensive Cancer Care and Faculty of MedicineMasaryk Memorial Cancer Institute and Masaryk UniversityBrnoCzech Republic
  2. 2.Institute of Biostatistics and Analyses, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  3. 3.Department of OncologyPalacky University Medical School and Teaching HospitalOlomoucCzech Republic
  4. 4.Department of Oncology, First Faculty of MedicineCharles University and General University HospitalPragueCzech Republic
  5. 5.Department of Oncology and RadiotherapyUniversity HospitalPilsenCzech Republic
  6. 6.Biomedical Centre, Faculty of Medicine in PilsenCharles UniversityPragueCzech Republic
  7. 7.Department of Oncology, Second Faculty of MedicineCharles University and Motol University HospitalPragueCzech Republic
  8. 8.Department of Oncology, First Faculty of MedicineCharles University and Thomayer HospitalPragueCzech Republic

Personalised recommendations